Chronic liver disease

References

• Accuracy of the references is the responsibility of the author.
   Google Scholar
• Schiff L, Schiff ER. Diseases of the liver. 6th ed. Philadelphia: JB Lippincott, 1987
   Google Scholar
• Babb RR. Needle biopsy of the liver. West J Med 1989: 150: 39–42
   PubMedGoogle Scholar
• Van Ness MM, Diehl AM. Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes? Ann Intern Med 1989: 111: 473–8
   PubMed Web of Science ®Google Scholar
• Alcohol and the liver. (Editorial) Lancet 1968: 2: 670–1
   Google Scholar
• Lieber CA. Pathogenesis and early diagnosis of alcoholic liver injury. N Engl J Med 1978: 298: 888–93
   PubMed Web of Science ®Google Scholar
• Rubin E, Lieber CA. Alcohol-induced hepatic injury in non-alcoholic volunteers. N Engl J Med 1968: 278: 869–76
   PubMed Web of Science ®Google Scholar
• Lelbach WK. Leberschaden bei chronischem Alkoholismus. Acta Hepatosplenogica 1966: 13: 321–49
   Google Scholar
• Cohen JA, Kaplan MM. The SGOT/SGPT ratio: an indicator of alcoholic liver disease. Am J Dig Dis 1979: 24: 835–8
   Google Scholar
• Rakela J, Redeker AC, Edwards VM, et al. Hepatitis A virus infection in fulminant hepatitis and chronic active hepatitis. Gastroenterology 1978: 74: 879–82
   PubMed Web of Science ®Google Scholar
• Gocke DA. Hepatitis A revisited. Ann Intern Med 1986: 105: 960
   PubMed Web of Science ®Google Scholar
• Boyer JL. Chronic hepatitis: a perspective on classification and determination of prognosis. Gastroenterology 1976: 70: 1161–71
   PubMed Web of Science ®Google Scholar
• Czaja AJ. Current problems in the diagnosis and management of chronic active hepatitis. Mayo Clin Proc 1981: 56: 311–23
   PubMed Web of Science ®Google Scholar
• Weissberg JL, Andres LL, Smith CI, et al. Survival in chronic hepatitis B. Ann Intern Med 1984: 101: 613–6
   PubMed Web of Science ®Google Scholar
• Davis GL, Czaja AJ. Current concepts in the diagnosis and management of hepatitis B surface antigen—positive chronic active hepatitis. J Clin Gastroenterology 1981: 3: 381–8
   PubMed Web of Science ®Google Scholar
• Redeker AG. Treatment of chronic active hepatitis: good news and bad news. N Engl J Med 1981: 304: 420–1
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH, Peters M, Mullen KD, et al. Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterology 1988: 95: 1318–25
   PubMed Web of Science ®Google Scholar
• Perrillo RP, Schiff ER, Davis GL, et al. A randomized, controlled trial of interferon alfa2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990: 323: 295–301
   PubMed Web of Science ®Google Scholar
• Korenman J, Baker B, Waggoner J, et al. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991: 114: 629–34
   PubMed Web of Science ®Google Scholar
• Di Bisceglie AM, Hoofnagle JH. Therapy of chronic hepatitis C with alpha-interferon: The answer? Or more questions? (Editorial) Hepatology 1991: 13: 601–3
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Davis GL, Ludwig J, et al. Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. Gastroenterology 1988: 85: 713–7
   Google Scholar
• Wright EC, Seef LB, Berk PD, et al. Treatment of chronic active hepatitis. Gastroenterology 1977: 73: 1422–30
   PubMed Web of Science ®Google Scholar
• Alter HJ. Descartes before the horse: I clone, therefore I am: The hepatitis C virus in current perspective. Ann Intern Med 1991: 115: 644–9
   PubMed Web of Science ®Google Scholar
• Hsu HM, Gonzalez M, Fuong SK, et al. Antibodies to hepatitis C virus in low-risk blood donors: implications for counseling positive donors. Gastroenterology 1991: 101: 1724–7
   PubMed Web of Science ®Google Scholar
• DeCock KM, Govindarajan S, Chin KP, et al. Delta hepatitis in the Los Angeles area. Ann Intern Med 1986: 105: 108–14
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH. Type D (delta) hepatitis. JAMA 1989: 261: 1321–5
   PubMed Web of Science ®Google Scholar
• Ludwig J. Drug effects on the liver. Dig Dis Sci 1979: 24: 785–96
   PubMed Web of Science ®Google Scholar
• Kaplowitz N. Drug-induced hepatotoxicity. Ann Intern Med 1986: 104: 826–39
   PubMed Web of Science ®Google Scholar
• Babb RR. Analgesic hepatotoxicity. West J Med 1978: 129: 164–5
   PubMedGoogle Scholar
• Kaplan MM. Primary biliary cirrhosis. N Engl J Med 1987: 316: 521–8
   PubMed Web of Science ®Google Scholar
• Boyer JL. Definitive therapy for primary biliary cirrhosis: fact or fiction. Gastroenterology 1988: 95: 242–5
   PubMed Web of Science ®Google Scholar
• Levschner V, Fisher H, Kurtz W, et al. Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. Gastroenterology 1989: 92: 1268–74
   Google Scholar
• Poupon RE, Balkan B, Eschwege E, et al. A multicenter controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 1991: 324: 1548–54
   PubMed Web of Science ®Google Scholar
• Wiesner RH, LaRusso NF. Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology 1980: 79: 200–6
   PubMed Web of Science ®Google Scholar
• Wiesner RH, LaRusso NF, Ludwig J, et al. Comparison of primary sclerosing cholangitis and primary biliary cirrhosis. Gastroenterology 1985: 88: 108–14
   PubMed Web of Science ®Google Scholar
• Porayko MK, Wiesner RH, LaRusso, et al. Patients with asymptomatic primary sclerosing cholangitis frequently have progressive disease. Gastroenterology 1990: 98: 1594–1602
   PubMed Web of Science ®Google Scholar
• Smith LH. Overview of hemochromatosis. West J Med 1990: 153: 296–308
   PubMedGoogle Scholar
• Niederan C, Fischer R, Sonnenberg A, et al. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985: 313: 1256–62
   PubMed Web of Science ®Google Scholar
• Dobyas WB, Goldstein N, Gordon H. Clinical spectrum of Wilson's disease. Mayo Clin Proc 1979: 54: 35–42
   PubMed Web of Science ®Google Scholar
• Schilsky ML, Scheinberg IH, Sternlieb I. Prognosis of Wilsonian chronic active hepatitis. Gastroenterology 1991: 100: 762–7
   PubMed Web of Science ®Google Scholar
• Stremmel W, Meyerrose KW, Niederau C, et al. Wilson disease: clinical presentation, treatment, and survival. Ann Intern Med 1991: 115: 720–6
   PubMed Web of Science ®Google Scholar
• Rakele J, Goldschmiedt M, Ludwig J. Late manifestations of chronic liver disease in adults with alpha-1-antitrypsin deficiency. Dig Dis Sci 1987: 32: 1358–62
   PubMed Web of Science ®Google Scholar
• Ware AJ. The liver when the heart fails. Gastroenterology 1978: 74: 627
   PubMed Web of Science ®Google Scholar
• Mitchell MM, Boitnott JK, Kaufman S, et al. Budd-Chiari syndrome: etiology, diagnosis and management. Medicine 1983: 61: 199–218
   Web of Science ®Google Scholar
• Summerskill WH, Shorter RG. Progressive hepatic failure: its association with undifferentiated renal tumor. Arch Intern Med 1967: 120: 81–4
   PubMedGoogle Scholar
• Di Bisceglie AM, Order SE, Klein JC, et al. The role of chronic viral hepatitis in hepatocellular carcinoma in the United States. Am J Gastroenterol 1991: 86: 325–38
   Google Scholar
• Ellis JC. Screening for hepatocellular carcinoma. West J Med 1988: 149: 183–6
   PubMedGoogle Scholar
• Starzl TE, Demetris AJ, Van Thiel D. Liver transplantation. N Engl J Med 1989: 321: 1014–22, 1092–9
   PubMed Web of Science ®Google Scholar